CURE Pharmaceutical Announces Entrance Into Booming Pharmaceutical Cannabis Industry

CURE to leverage novel drug delivery technologies to bring new cannabinoid molecules to market

Print
| Source: CURE Pharmaceutical

Oxnard, Calif., May 10, 2017 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (OTCQB:CURR), (“CURE”), a leading disruptive drug delivery technology company researching and developing drug and cannabinoid molecules for various healthcare applications, announced today its formal entrance into the pharmaceutical cannabis sector, which in the U.S. is estimated to reach over $23 billion by 2020, according to ArcView Market Research.

CURE has developed a pharmaceutical cannabinoid division to research and develop clinically ready cannabinoid drug formulations and delivery systems for both human and/or animal patients and is developing a global footprint with partners in the U.S., Canada, Israel and Germany, among other markets. The Company has taken a leadership role in optimizing plant base cannabinoids by vertically integrating drug discovery, proprietary extraction technology, genetic-specific cannabinoids research, and drug development. 

“We are well-positioned in the pharmaceutical cannabis sector and excited to work within an industry with such a promising future,” said Rob Davidson, CEO of CURE. “Our goal is to bring new cannabinoid molecules to the market through the FDA regulatory process, while utilizing our company’s proprietary delivery technologies to increase efficacy, as well as target unmet needs in traditional pharmaceutical markets that could be disrupted by cannabinoid-based options.”

CURE is researching and developing proprietary formulas of different cannabinoids and terpene profiles integrated into its advanced oral thin film, CureFilm™ and transdermal applications leveraging its proprietary polymer and encapsulation technology. The Company is focusing on integrating its proprietary delivery systems to provide solutions to conditions like pain, neuropathy, cancer (including pediatric cancer), PTSD and other psychiatric disorders, autoimmune diseases, Parkinson’s disease and sleep disorders.  


The Company is already actively forming several cannabinoid drug molecule partnerships and collaborations with some top healthcare and cannabis industry organizations globally. CURE is dedicated to providing knowledgeable updates on all of these partnerships and the innovative work they will be conducting.

About CURE Pharmaceutical
CURE Pharmaceutical is a fully integrated specialty pharmaceutical/bioscience company with disruptive proprietary drug delivery technologies for a broad range of molecules serving the pharmaceutical, biotech, veterinarian, medical foods markets, cannabinoid molecules and new chemical entities (NCEs). The Company’s mission is to create solutions to improve the overall quality of life and deliver proven drugs in a fast and efficient manner. CURE has an industry leading full service cGMP manufacturing facility. They have developed an array of products in cutting-edge delivery platforms and is the preeminent developer and manufacturer of a patented and proprietary delivery system (CureFilm™), the most advanced oral thin film on the market today. CURE is well positioned in the pharmaceutical cannabis sector and is developing a global footprint with partners in the U.S., Canada, Israel and Germany, among other global markets.

For more information about CURE Pharmaceutical, please visit its website at www.curepharmaceutical.com

Forward-looking statements
This press release contains forward-looking statements, which are subject to risks and uncertainties. All statements, other than statements of fact, including those statements with respect to the Company's business development, are forward-looking statements. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.

Contact:
Andrew Hard
CMW Media
Andrew.hard@cmwmedia.com
917.660.5418